Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/01/2005CA2566747A1 Topical cromolyn formulations
12/01/2005CA2566746A1 Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
12/01/2005CA2566741A1 Acyclovir formulations
12/01/2005CA2566688A1 Transthyretin stabilization
12/01/2005CA2566675A1 Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering a bone anabolic agent
12/01/2005CA2566612A1 Uridine effects on dopamine release
12/01/2005CA2566466A1 Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
12/01/2005CA2566445A1 Methods related to the treatment of neurodegenerative and inflammatory conditions
12/01/2005CA2566444A1 Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
12/01/2005CA2566387A1 Aryl sulfonamides as chemokine receptor ccr9 antagonists
12/01/2005CA2566204A1 Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
12/01/2005CA2566174A1 Treatment of lung diseases and pre-lung disease conditions
12/01/2005CA2566104A1 Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
12/01/2005CA2566090A1 Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
12/01/2005CA2566081A1 Use of dipyridamole for treatment of resistance to platelet inhibitors
12/01/2005CA2566062A1 Treatment or prevention of respiratory viral infections with immunomodulator compounds
12/01/2005CA2566053A1 Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
12/01/2005CA2565747A1 Medicinal aerosol formulation products with improved chemical stability
12/01/2005CA2565519A1 Cxcr1 and cxcr2 chemokine antagonists
12/01/2005CA2565448A1 Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors
12/01/2005CA2565447A1 Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
12/01/2005CA2565446A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
12/01/2005CA2565445A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
12/01/2005CA2565416A1 Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds
12/01/2005CA2565200A1 Raf modulators and methods of use
12/01/2005CA2565188A1 Compounds and compositions for delivering active agents
12/01/2005CA2564963A1 Steroid prodrugs with androgenic effect
12/01/2005CA2564530A1 Thieno[3,2-b]pyridine-6-carbonitriles as protein kinase inhibitors
12/01/2005CA2564365A1 Compounds and compositions as ppar modulators
12/01/2005CA2564332A1 Powders containing novel oligosaccharide mixtures and methods for producing the same
12/01/2005CA2564215A1 Substituted quinoline derivatives as mitotic kinesin inhibitors
12/01/2005CA2564076A1 Chemical linkers and conjugates thereof
12/01/2005CA2563979A1 Geldanamycin compounds and method of use
12/01/2005CA2563968A1 Neurogenic pain control agent composition
12/01/2005CA2563908A1 Metabolites of selective androgen receptor modulators and methods of use thereof
12/01/2005CA2563801A1 Modulation of glucose-6-phosphatase translocase expression
12/01/2005CA2563432A1 Method for augmenting b cell depletion
12/01/2005CA2562915A1 Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake
12/01/2005CA2562904A1 Cancer treatment using viruses and camptothecins
12/01/2005CA2562783A1 Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
12/01/2005CA2562065A1 Carbocyclic and heterocyclic polysulfides useful in the treatment of cancer and other proliferative disorders
12/01/2005CA2562027A1 Substituted pyrrole-2, 5-diones as protein kinase c inhibitors
12/01/2005CA2556921A1 Levalbuterol hydrochloride polymorph b
12/01/2005CA2556920A1 Levalbuterol hydrochloride polymorph a
12/01/2005CA2556904A1 Preparation of levalbuterol hydrochloride
12/01/2005CA2551613A1 A composition comprising n-acetyl-d-glucosamine for treatment of wound
12/01/2005CA2544950A1 Method for the catalytic production of hydrocodone and hydromorphone
12/01/2005CA2508585A1 Transdermal delivery system for treatment of cognitive disorders
12/01/2005CA2469427A1 Dry mixed dosage form containing benzimidazole derivatives
11/2005
11/30/2005EP1600506A2 Oligoribonucleotides and ribonucleases for cleaving RNA
11/30/2005EP1600454A1 Anti-influenza virus compound comprising biflavonoid-sialic acid glycoside
11/30/2005EP1600452A2 Synthesis of 2'-deoxy-L-nucleosides
11/30/2005EP1600451A2 Synthesis of 2'-deoxy-l-nucleosides
11/30/2005EP1600448A2 Enantiomerically pure beta-D-(-)-Dioxolane-Nucleosides
11/30/2005EP1600445A1 Medicinal composition
11/30/2005EP1600442A1 Heteroarylcarbamoylbenzene derivative
11/30/2005EP1600441A2 Novel crystalline form of lercanidipin hydrochloride and processes for its preparation
11/30/2005EP1600210A1 Charged microspheres
11/30/2005EP1600180A2 Antiproliferative drug and delivery device
11/30/2005EP1600170A1 Sustained-release pharmaceutical composition for lung administration
11/30/2005EP1600169A2 A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
11/30/2005EP1600168A2 A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
11/30/2005EP1600167A2 A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
11/30/2005EP1600166A1 Skeletal muscle protecting agent
11/30/2005EP1600161A2 Processes for preparing 13-deoxyanthracycline derivatives as anticancer of low cardio toxicity
11/30/2005EP1600160A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
11/30/2005EP1600159A1 A method for synthesizing different Zolpidem hemitartrate derivatives
11/30/2005EP1600158A1 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
11/30/2005EP1600157A1 Enteric sustained-release fine particles for tamsulosin or its salt and process for producing the same
11/30/2005EP1600156A2 Combination treatment for impaired motor function in parkinson's disease
11/30/2005EP1600155A1 The use of polyols in combating yeast infection and polyol preparations for said use
11/30/2005EP1600154A1 Osmotic extended-release dosage form
11/30/2005EP1600153A1 Slow-release pharmaceutical composition allowing to monitor drug release
11/30/2005EP1600143A1 SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
11/30/2005EP1600063A1 Composition to improve the endurance
11/30/2005EP1600062A1 Oral and/or topical compositions comprising prebiotics and sterols
11/30/2005EP1600061A1 Oral and/or topical compositions
11/30/2005EP1600060A1 Oral and/or topical compositions comprising prebiotics and fatty acid
11/30/2005EP1599726A2 Selective modulation of tlr-mediated biological activity
11/30/2005EP1599593A2 Use of a tricyclic antidepressant drug for promoting endocytosis
11/30/2005EP1599573A2 Model for studying the role of genes in tumor resistance to chemotherapy
11/30/2005EP1599501A2 Modulation of the poliovirus receptor function
11/30/2005EP1599493A1 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action
11/30/2005EP1599485A2 Podophyllotoxin derivatives as antitumor agents
11/30/2005EP1599484A2 Process for the preparation of hexacyclic camptothecin derivatives
11/30/2005EP1599482A1 Pyrazolo 1,5-a pyrimidine derivatives
11/30/2005EP1599481A1 6-substituted imidazopyrazines
11/30/2005EP1599480A1 Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments
11/30/2005EP1599479A1 Substituted imidazotriazines
11/30/2005EP1599476A1 Novel diazabicyclic aryl derivatives
11/30/2005EP1599475A2 Jnk inhibitors
11/30/2005EP1599473A1 Imidazo 4,5-b quinoline-derivatives and their use as no-synthase inhibitors
11/30/2005EP1599470A1 Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them
11/30/2005EP1599469A1 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
11/30/2005EP1599468A1 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
11/30/2005EP1599467A1 Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
11/30/2005EP1599466A2 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
11/30/2005EP1599461A1 Thiolactones
11/30/2005EP1599455A1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
11/30/2005EP1599454A2 Diarylcycloalkyl derivatives, method for their production and their use as medicaments
1 ... 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 4469 4470 4471 ... 7860